This is a Validated Antibody Database (VAD) review about human PTPN5, based on 8 published articles (read how Labome selects the articles), using PTPN5 antibody in all methods. It is aimed to help Labome visitors find the most suited PTPN5 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
PTPN5 synonym: PTPSTEP; STEP; STEP61; tyrosine-protein phosphatase non-receptor type 5; neural-specific protein-tyrosine phosphatase; protein tyrosine phosphatase, non-receptor type 5 (striatum-enriched); protein-tyrosine phosphatase striatum-enriched; striatal-enriched protein tyrosine phosphatase; striatum-enriched protein-tyrosine phosphatase

Santa Cruz Biotechnology
mouse monoclonal (23E5)
  • western blot; rat; 1:1000; loading ...; fig s1
In order to explore the contribution of STEP61 to the therapeutic effects of D-serine in patients with schizophrenia, Santa Cruz Biotechnology PTPN5 antibody (Santa Cruz Biotechnology, 23E5) was used in western blot on rat samples at 1:1000 (fig s1). Mol Neurobiol (2018) ncbi
mouse monoclonal (23E5)
  • western blot; mouse; 1:1000; loading ...; fig 4a
In order to investigate the impact of locked nucleic acid-modified antisense oligonucleotide complementary to the CAG repeat on Huntington's disease, Santa Cruz Biotechnology PTPN5 antibody (Santa Cruz, sc-23892) was used in western blot on mouse samples at 1:1000 (fig 4a). J Clin Invest (2016) ncbi
mouse monoclonal (23E5)
  • western blot; rat; fig 1
Santa Cruz Biotechnology PTPN5 antibody (Santa Cruz, SC-23892) was used in western blot on rat samples (fig 1). Neural Plast (2016) ncbi
mouse monoclonal (23E5)
  • western blot; mouse; 1:500
In order to study temporal changes in STEP61 expression, activation and signaling in a murine model of Huntington's disease, Santa Cruz Biotechnology PTPN5 antibody (Santa Cruz Biotechnology, sc-23892) was used in western blot on mouse samples at 1:500. J Neurochem (2014) ncbi
Invitrogen
mouse monoclonal (23E5)
  • western blot; rat; 1:1000; fig 5
In order to study how cellular localization affects DHHC5 activity, Invitrogen PTPN5 antibody (Life Technologies, MA1-16746) was used in western blot on rat samples at 1:1000 (fig 5). Nat Commun (2015) ncbi
Novus Biologicals
mouse monoclonal (2.30E+06)
  • western blot; rat
In order to study the distinct roles of different calpain isoforms in synaptic neuroprotection and extrasynaptic neurodegeneration mediated by the NMDA receptor, Novus Biologicals PTPN5 antibody (Novus, NB300-202) was used in western blot on rat samples . J Neurosci (2013) ncbi
Cell Signaling Technology
rabbit monoclonal (D7E2)
  • immunohistochemistry; mouse; 1:100; loading ...; fig 2c
Cell Signaling Technology PTPN5 antibody (Cell Signaling, 9017) was used in immunohistochemistry on mouse samples at 1:100 (fig 2c). Cell Death Differ (2018) ncbi
rabbit polyclonal
  • western blot; human; 1:100; fig st1
In order to identify and characterize alterations in signal transduction that occur during the development Lapatinib resistance, Cell Signaling Technology PTPN5 antibody (Cell Signaling, 4817) was used in western blot on human samples at 1:100 (fig st1). Nat Commun (2016) ncbi
EMD Millipore
rabbit polyclonal
  • western blot; mouse; 1:200
In order to study temporal changes in STEP61 expression, activation and signaling in a murine model of Huntington's disease, EMD Millipore PTPN5 antibody (EMD Millipore, AB2208) was used in western blot on mouse samples at 1:200. J Neurochem (2014) ncbi
Articles Reviewed
  1. Guo S, Zhang Y, Zhou T, Wang D, Weng Y, Chen Q, et al. GATA4 as a novel regulator involved in the development of the neural crest and craniofacial skeleton via Barx1. Cell Death Differ. 2018;25:1996-2009 pubmed publisher
  2. Xu J, Kurup P, Nairn A, Lombroso P. Synaptic NMDA Receptor Activation Induces Ubiquitination and Degradation of STEP61. Mol Neurobiol. 2018;55:3096-3111 pubmed publisher
  3. Rue L, Bañez Coronel M, Creus Muncunill J, Giralt A, Alcalá Vida R, Mentxaka G, et al. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels. J Clin Invest. 2016;126:4319-4330 pubmed publisher
  4. Treindl F, Ruprecht B, Beiter Y, Schultz S, Döttinger A, Staebler A, et al. A bead-based western for high-throughput cellular signal transduction analyses. Nat Commun. 2016;7:12852 pubmed publisher
  5. Jang S, Royston S, Lee G, Wang S, Chung H. Seizure-Induced Regulations of Amyloid-?, STEP61, and STEP61 Substrates Involved in Hippocampal Synaptic Plasticity. Neural Plast. 2016;2016:2123748 pubmed publisher
  6. Brigidi G, Santyr B, Shimell J, Jovellar B, Bamji S. Activity-regulated trafficking of the palmitoyl-acyl transferase DHHC5. Nat Commun. 2015;6:8200 pubmed publisher
  7. Gladding C, Fan J, Zhang L, Wang L, Xu J, Li E, et al. Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model. J Neurochem. 2014;130:145-59 pubmed publisher
  8. Wang Y, Briz V, Chishti A, Bi X, Baudry M. Distinct roles for ?-calpain and m-calpain in synaptic NMDAR-mediated neuroprotection and extrasynaptic NMDAR-mediated neurodegeneration. J Neurosci. 2013;33:18880-92 pubmed publisher